Recent animal work has suggested that injection of human pCRP can increase myocardial infarct size in a rat myocardial Background-The relevance of the dissociation of circulating pentameric C-reactive protein (pCRP) to its monomeric subunits (mCRP) is poorly understood. We investigated the role of conformational C-reactive protein changes in vivo. Methods and Results-We identified mCRP in inflamed human striated muscle, human atherosclerotic plaque, and infarcted myocardium (rat and human) and its colocalization with inflammatory cells, which suggests a general causal role of mCRP in inflammation. This was confirmed in rat intravital microscopy of lipopolysaccharide-induced cremasteric muscle inflammation. Intravenous pCRP administration significantly enhanced leukocyte rolling, adhesion, and transmigration via localized dissociation to mCRP in inflamed but not noninflamed cremaster muscle. This was confirmed in a rat model of myocardial infarction. Mechanistically, this process was dependent on exposure of lysophosphatidylcholine on activated cell membranes, which is generated after phospholipase A2 activation. These membrane changes could be visualized intravitally on endothelial cells, as could the colocalized mCRP generation. Blocking of phospholipase A2 abrogated C-reactive protein dissociation and thereby blunted the proinflammatory effects of C-reactive protein.
C
-reactive protein (CRP) belongs to the pentraxin family of protein and circulates as a pentamer of 5 identical, noncovalently linked subunits in plasma. Recently, a dissociation mechanism on activated platelets that leads to a conformational change from the circulating native, pentameric CRP (pCRP) to its monomeric subunits (mCRPs) has been identified. 1 This dissociation is mediated by bioactive lipids 2 found on activated or damaged cells or platelets 1, 3 and leads to an alteration of the proinflammatory profile of the protein. 4 
Clinical Perspective on p 50
With respect to the inflammatory properties of the 2 isoforms, it has been shown that dissociation of pCRP to mCRP leads to increased activation, adhesion, and transmigration of monocytes, as well as formation of reactive oxygen species in vitro, 1 which represent major pathophysiological factors that contribute to tissue injury in inflammation.
infarction model, which can be reduced by a CRP-blocking reagent. 5 In a vascular injury model in transgenic mice, CRP led to increased neointima formation. 6 Animal models of myocardial infarction, 5, 7 stroke, 8 and intestinal ischemia/ reperfusion 9 have found that infusion of CRP increases tissue damage. To date, it remains unclear whether the recently described pCRP dissociation to mCRP is of relevance in vivo and how it potentially contributes to the aforementioned findings. Furthermore, our understanding of the pathophysiology of CRP dissociation is mainly based on in vitro findings, and overall, the mechanisms and mediators involved are poorly understood.
Phospholipase A2 (PLA2) enzymes modify the composition of cellular membranes by releasing fatty acids from the sn2 position of phospholipids, which leads to the formation of arachidonic acid and lysophospholipids. 10 Arachidonic acid is further processed into bioactive eicosanoids, including prostaglandins and leukotrienes. Lysophospholipids can be further modified to platelet-activating factor (PAF). All these molecules are potent regulators of inflammation. 10, 11 Because binding of CRP is enhanced on lysophosphatidylcholine-enriched membranes, we hypothesized that there is a link between PLA2 activation and CRP dissociation.
Here, we investigated the role of conformational changes in CRP in vivo and aimed to elucidate the underlying mechanisms, including the role of PLA2-mediated membrane changes. Furthermore, we aimed to identify the CRP dissociation process as a therapeutic target.
Methods
Reagents pCRP purified from human ascites (Merck, Darmstadt, Germany) was dialyzed against phosphate-buffered physiological saline solution with Ca 2+ and Mg 2+ (PBS-Ca-Mg; Biochrom, Berlin, Germany) before use with a Slide-A-Lyzer Dialysis Cassette (Pierce Biotechnology, Rockford, IL). For subsequent application, the final concentration of pCRP was determined (BCA, Sigma-Aldrich, St. Louis, MO).
12,13 mCRP (1 mg/mL in Na-PBS) was used in the soluble, citraconylated form and prepared as described previously. 14 In awareness of potential problems with bacterial contamination in CRP preparations, 15 all reagents were tested for lipopolysaccharide (LPS) contamination with a Limulus assay (Sigma-Aldrich) and found to be below the detection limit (0.125 U/mL or 0.01 ng/mL LPS). CRP purity and spontaneous mCRP formation were ruled out by Western blotting with 1/20th of normal levels of sodium dodecyl sulfate of pCRP and mCRP preparations to avoid confounding by contamination of other CRP isoforms.
All animal studies were approved by the institutional review board of the University of Freiburg Medical Center (Freiburg, Germany), and procedures were performed in accordance with institutional guidelines. Studies that involved human tissue samples were approved by the institutional review committee, and the subjects gave informed consent to the use of the tissue samples for this study.
Statistical Analysis
Analysis of data were performed with GraphPad Prism version 5.0 software (GraphPad Software, San Diego, CA). For comparison of 2 groups, a 2-tailed t test was used. A P value <0.05 was considered statistically significant. All experiments were performed ≥3 times. Data are expressed as mean±SEM. A 1-way ANOVA to compare the effects of different treatments was used if >2 groups were compared. In case of significance, the Tukey test was used for pairwise comparison. Only significant results for both ANOVA and Tukey test are presented. For analysis of the aptamer-specific binding to mCRP but not pCRP, we used a 1-way ANOVA with repeated measures to compare the groups with different concentrations. To analyze treatment effects over time, we performed a 2-way repeated-measures (mixed model) ANOVA with the fixed factors of time and treatment and the corresponding interaction term. Additionally, the random factor animal was included in the model. In case of a nonsignificant interaction and significant treatment effect, pairwise Bonferroni adjusted comparisons were performed at each time point. Significant results for both 2-way repeated-measures (mixed model) ANOVA and Bonferroni post hoc tests are presented.
An expanded Methods section is available in the online-only Data Supplement.
Results

CRP Is Deposited in Inflamed Human Tissue as mCRP and Colocalizes With Monocytes/ Macrophages
In the human muscle biopsy samples of ischemia/reperfusion injury, we detected mCRP but not pCRP in the postischemic tissue samples, which colocalized with CD68-positive monocytes ( Figure 1A ). The postischemic increases in mCRP expression and CD68-positive cells showed a similar tendency ( Figure 1B) .
To analyze the potential relevance of mCRP deposition in the pathogenesis of tissue damage in humans, infarcted myocardial tissue samples were obtained from autopsy specimens that originated from patients who had had a myocardial infarction 2 to 4 days before death. Sections taken from infarcted and noninfarcted tissue were stained with antibodies specific for mCRP and pCRP. There was extensive deposition of mCRP in infarcted regions, with very limited deposition in noninfarcted areas ( Figure 1C ). We identified a perivascular distribution of mCRP staining.
Inflamed atherosclerotic plaques obtained from human carotid endarterectomy samples were stained with pCRP-, mCRP-, and CD68-specific antibodies ( Figure 1D ). mCRP was detected in the necrotic core of atherosclerotic lesions and colocalized with macrophages.
CRP Aggravates the Inflammatory Response via Interaction With the Complement System, but CRP Does Not Show Intrinsic Proinflammatory Properties
In an intravital microscopy model of microcirculation changes in the rat cremaster muscle, low-dose LPS superfusion caused a mild inflammatory response that resulted in increased leukocyte rolling and adhesion (Figure 2A and 2B), as well as endothelial membrane changes, detected by in vivo annexin V staining of endothelial cells ( Figure 2E ). pCRP infusion did not induce leukocyte rolling or adhesion in the resting muscle tissue. In inflamed muscle tissue after LPS superfusion, CRP aggravated the preexisting inflammatory response as measured by leukocyte rolling, adhesion (Figure 2A and 2B), and monocyte transmigration ( Figure 2C and 2D) . Similar effects were observed in isolated rat monocytes ex vivo ( Figure 2F ).
The proinflammatory, tissue-damaging effects of human CRP in vivo are dependent on complement. 7 To show that the observed effects were dependent on this CRP-complement interaction and to exclude confounding by endogenous rat CRP, we analyzed the role of the complement system in CRPinduced leukocyte activation via depletion of complement. Intraperitoneal injection of cobra venom factor led to a significant reduction of complement activity compared with the control ( Figure I in the online-only Data Supplement). Complement depletion induced a significant decrease in leukocyte rolling after 60 minutes and adhesion at 80 minutes in the CRP-driven inflammation ( Figure I in the online-only Data Supplement).
These results indicate a dominant in vivo role of the complement system in the mCRP-triggered proinflammatory cascade.
CRP Is Transported Into Areas of Inflammation on Transmigrating Leukocytes and Is Deposited in Inflamed Tissue
Western blot analysis showed a deposition of CRP in LPSchallenged cremasteric muscle tissue but not in resting tissue as evaluated for the triceps muscle and heart and lung tissue ( Figure 3A through 3C). CRP in vivo tracking revealed that CRP could be detected on transmigrating leukocytes and was deposited in inflamed tissue ( Figure 3D ). Intravital staining of CRP and endothelial membrane changes (annexin V) showed that CRP/leukocyte transmigration was found in areas with endothelial membrane changes. In resting tissue, neither annexin V nor CRP was detected.
CRP Is Deposited as mCRP in Inflamed Tissue
Rat cremaster muscle samples were examined for CRP deposition by native Western blotting and immunohistochemistry by conformation-specific antibodies. Native Western blot analysis revealed that a majority of CRP deposited in the inflamed cremasteric tissue was in monomeric form. In noninflamed tissue (without LPS superfusion), CRP was found to a much reduced extent and only as pCRP ( Figure 3E and 3F). This was verified by immunohistochemistry of rat cremasteric muscle after microcirculation experiments. In the control group and LPS group, no CRP was detected. After pCRP injection, without inflammatory stimulus to the cremasteric tissue, trace amounts of pCRP were detected by immunohistology. LPS-induced localized cremasteric inflammation led to deposition and detection of mCRP ( Figure 3G and 3H).
mCRP Induces Adhesion of Human and Rat Monocytes and Generation of ROS
In an in vitro monocyte adhesion assay, mCRP induced a significant increase in leukocyte adhesion to a fibrinogen matrix compared with the control that was comparable to high-dose stimulation with LPS in both rat ( Figure 4A ) and human ( Figure 4B ) monocytes. This finding underlines the physiological 
Inhibition of PLA2 Prevents CRP Dissociation on Activated Cells
Several inhibitors of enzymes of the PLA2 family were used to analyze the effects on CRP dissociation. By native gel Western blot analysis, we were able to detect CRP dissociation on by guest on April 17, 2017 http://circ.ahajournals.org/ Downloaded from activated monocytes, as described previously. 1 Inhibition of PLA2 by ONO-RS, methyl arachidonyl fluorophosphonate, and aristolochic acid reduced mCRP formation, which suggests that CRP dissociation was mediated by expression of lysophosphatidylcholine (LPC) on cells through activation of PLA2 ( Figure 5A and 5B).
In vitro experiments demonstrated that LPS-induced PLA2 activity in mononuclear leukocytes could be decreased by preincubation of cells with ONO-RS ( Figure 5E ), thereby inhibiting the mCRP formation in a concentration-dependent manner, as evaluated by native gel electrophoresis. Concentrations of 10 μmol/L ONO-RS were able to produce a near-complete inhibition of CRP dissociation ( Figure 5C and 5D).
Inhibition of PLA2 In Vivo Inhibits Localized mCRP Formation and Leukocyte Activation
Using a concentration of 10 μmol/L ONO-RS superfusion of the cremasteric muscle tissue, we were able to demonstrate complete inhibition of the effects of CRP on leukocyte rolling at 120 minutes and on adhesion after 60 minutes. In contrast, LPS-mediated proinflammatory effects were not significantly inhibited compared with the LPS control ( Figure 6A and 6B ). This demonstrates that blocking of PLA2 in vivo inhibits mCRP generation and thereby prevents amplification of the inflammatory response. Localized CRP dissociation was observed intravitally by tracking of fluorescently labeled pCRP and detection of mCRP by an mCRP-specific fluorescently labeled aptamer. 16 Control experiments demonstrated that the aptamer was specific for mCRP and did not possess potential proinflammatory confounding effects ( Figure 6D and 6E). In vivo mCRP generation and transmigration into inflamed tissue were observed. This was abolished by blocking PLA2 with ONO-RS ( Figure 6C ). Because of the inhibition of mCRP generation, the fluorescently labeled pCRP remained detectable. This was associated with a lack of CRP detection in the inflamed tissue.
Stabilization of CRP and Prevention of CRP Dissociation Inhibits Proinflammatory CRP Properties In Vivo
1,6-Bis(phosphocholine)-hexane (1,6-bis PC) is able to stabilize pCRP in a decameric conformation and is able to inhibit its interactions with complement. 5 We demonstrated here that 1,6-bis PC also inhibited CRP dissociation to mCRP ( Figure 7A and 7B) in vitro. Using this stabilization of pCRP before injection, we demonstrated by native Western blotting of inflamed cremasteric tissue that 1,6-bis PC inhibited CRP deposition in inflamed tissue ( Figure 7C ). These data were confirmed by immunohistochemistry, which demonstrated that mCRP deposition in the inflamed muscle tissue was markedly decreased after stabilization of CRP with 1,6-bis PC ( Figure 7D ). This blocking effect resulted in inhibition of the CRP-mediated increase in leukocyte rolling after 60 minutes and adhesion at 120 minutes ( Figure 7E and 7F) . This demonstrates the feasibility of this potential therapeutic approach and the central importance of pCRP dissociation in the unmasking of proinflammatory CRP effects.
mCRP and pCRP Deposition Is Localized to Infarcted Myocardial Tissue in a Rat Model of Ischemia/Reperfusion Injury
To confirm the relevance of CRP dissociation in a disease model, we examined the proposed mechanism and its inhibition by 1,6-bis PC in a rat left anterior descending coronary artery ligation model of myocardial infarction. Histological examination of rat myocardium showed extensive deposition of mCRP in infarcted tissue, as shown in Figure 7H . In contrast, in noninfarcted right ventricular segments ( Figure 7H , row 2), no mCRP could be detected. Furthermore, control samples, which were not infused with human pCRP ( Figure 7H , row 3), did not show any staining for mCRP. Small amounts of pCRP were detected in ischemic/reperfused tissue but in significantly lower amounts than mCRP. These findings were quantified by use of imaging analysis software, and the results are shown in Figure 7I . There was significantly more mCRP than pCRP identified in ischemic tissue segments. The nonischemic and vehicle controls did not show specific staining.
1,6-bis-PC Inhibits the Formation and Deposition of mCRP in Infarcted Tissue and Reduces the Localized Inflammatory Response
In the myocardial ischemia/reperfusion model, a third experimental group was infused with human pCRP together with 1,6-bis-PC. This agent was able to completely abolish the formation and deposition of mCRP ( Figure 7H ). The amount of both mCRP and pCRP detected was not significantly Figure 7H by use of image analysis software as described in Methods. Three slides of each animal were analyzed and averaged. The average counted as the value for 1 rat (n=6).
by guest on April 17, 2017 http://circ.ahajournals.org/ Downloaded from different from the vehicle and nonischemic controls, as shown in Figure 7I . The reduced mCRP formation and deposition by 1,6-bis-PC led to a significant reduction of leukocyte infiltration, expression of caspase 3 (a marker of apoptosis), and expression of the proinflammatory cytokines interleukin 6 and tumor necrosis factor-α (which served as surrogate parameters for the degree of tissue injury) compared with the CRP control ( Figure III in the online-only Data Supplement).
Discussion
Here, we have identified and characterized the role of pCRP dissociation to mCRP for the first time in vivo in an animal model of acute inflammation. This points to the CRP dissociation process as a potential therapeutic target. This is supported by the following findings: (1) mCRP was detected in human tissue samples of inflamed striated muscle tissue, human atherosclerotic plaques, and areas of infarcted rat and human heart tissue and was typically colocalized with inflammatory cells. These findings are consistent with a ubiquitous causal role in inflammation. (2) CRP was deposited in inflamed or ischemic tissue but not in healthy tissue beds. It aggravated the preexisting inflammatory response by inducing pathological leukocyte-endothelium interaction and generation of reactive oxygen species. pCRP did not demonstrate any intrinsic inflammatory properties without preexisting inflammatory tissue damage. (3) CRP was deposited in the area of inflammation as mCRP. (4) Localized pCRP dissociation was dependent on PLA2-mediated endothelial membrane changes and exposure of LPC, which localized mCRP-induced inflammation to areas of PLA2 activation. The blocking of PLA2 by pharmacological inhibitors abrogated these membrane changes and resulted in inhibition of CRP dissociation and prevention of the proinflammatory effects of CRP in vivo. (5) mCRP had marked proinflammatory properties in vitro and in vivo. mCRP deposits in tissue promoted monocyte chemotaxis and recruited circulating leukocytes to areas of inflammation via Fcγ-RI and Fcγ-IIIa signaling. (6) mCRP was transported into inflamed tissue bound to transmigrating leukocytes. (7) 1,6-Bis-PC inhibited pCRP dissociation and inhibited CRP deposition in inflamed tissue. By preventing mCRP formation 1,6-bis-PC inhibited proinflammatory CRP effects in inflamed tissue. This hypothesis was confirmed in a rat model of myocardial infarction in which the therapeutic use of 1,6-bis-PC prevented localized mCRP formation and deposition within the infarcted tissue and in turn reduced the parameters of tissue injury and inflammation. (8) mCRP induced leukocyte rolling and adhesion via a complement-dependent mechanism. These results are summarized in the schematic drawing in Figure 8 .
To verify the pathophysiological relevance of mCRP in vivo, we used a rat model, because even though rats have abundant CRP (300-600 μg/mL in normal, healthy, pathogen-free rats), it does not activate rat complement. 17 This is in contrast to human CRP, which activates both rat and human complement but not mouse complement, 18 which is a major limitation to the use of mice in CRP research. Depletion of complement abrogated the effects of CRP, which confirms the crucial role that complement plays in CRP pathophysiology. 6, 7 One limitation of the use of rats is the limited availability of knockout animals. Therefore, we used a pharmacological approach to suppress PLA2 activity with a range of specific inhibitors to characterize its fundamental mechanistic role in CRP dissociation. However, this approach does not completely rule out the contribution of other unknown factors to the observed effects. Because PLA2 inhibition showed no effect on LPS-induced inflammation without the addition of pCRP, the present results show that PLA2 inhibition influences the effects of CRP-mediated exacerbation of inflammation. Further interpretations of the role of PLA2 in this context must be undertaken on the basis of the natural limitations of the experimental strategy, because the mechanism of the PLA2 inhibitors may be indirect or confounded by unidentified off-target effects.
To prove the ubiquitous character of the proinflammatory mechanism of localized pCRP dissociation, we analyzed mCRP in human infarcted myocardial tissue and in atherosclerotic plaques. In human myocardial tissue, pCRP could not be detected, which indicates that all bound pCRP underwent dissociation within hours of infarction. These findings were confirmed in a rat model of left anterior descending coronary artery ligation. The local deposition of mCRP was limited to areas of ischemic/necrotic tissue. In human atherosclerotic plaques, we showed that mCRP deposition was localized to the necrotic core of the lesion. Overall, these findings support the notion that CRP dissociation modulates inflammation in acute (cardiac ischemia/reperfusion) and chronic (atherosclerosis) inflammatory processes.
PLA2 enzymes are regulators of inflammation, 11 which is supported by the finding of reduced postischemic brain injury in a knockout mouse model deficient in cytosolic PLA2. Conversely, overexpression of Ca 2+ -independent PLA2-β led to increased vascular inflammation in a vascular ligation model in mice. 20 In addition to the release of arachidonic acid, activation of PLA2 results in the production of LPC. Generation of LPC via activation of the Ca 2+ -independent PLA2 and exposure of LPC on the cell surface is a mechanism generally identified in activated or apoptotic cells. 21 Lauber et al 22 identified Ca 2+ -independent PLA2 activation in apoptotic cells and subsequent LPC generation as a "find me" signal for macrophages. We visualized these membrane changes in vivo by expression of phosphatidylserine on endothelial cells detected by annexin V binding. Phosphatidylserine surface expression and LPC generation both are events in the early phase of cell damage 23 and present an "eat me" signal for macrophages. 24 Both phospholipids (phosphatidylserine and LPC) are central to the signaling pathways of apoptosis, and both are expressed on activated cell membranes and microparticles. 25, 26 Thus, annexin V binding is a suitable parameter to monitor membrane changes and a suitable surrogate marker for the surface expression of LPC, because the expression of LPC and the expression of phosphatidylserine are concurrent events. For the first time, we were able to observe localized CRP dissociation in vivo by intravital imaging of the microcirculation of inflamed tissue by means of a specific fluorescently labeled anti-mCRP aptamer. 16 This localized mCRP generation was completely inhibited after PLA2 was blocked in vivo.
In the present experiments, LPS was used to activate PLA2 27 and facilitate LPC formation. This enabled the binding of circulating pCRP 28 and subsequent conformational changes of the protein.
1,2 The present findings complete the understanding of this inflammatory pathway. In addition to direct chemoattraction by LPC, 22 the conformational change of CRP is an activation signal to circulating leukocytes that marks the area of inflammation by localized deposition. These findings identify a novel mechanism by which PLA2 regulates inflammation.
Recently, a role for lipoprotein-associated, PLA2-generated LPC has been postulated for human atherosclerotic plaque formation. 29 We previously described the localized dissociation and deposition of mCRP in atherosclerotic plaques. 1 PLA2-mediated membrane changes and subsequent CRP dissociation may therefore be a ubiquitous mechanism in chronic inflammatory conditions such as atherosclerosis. This event is dependent on the expression of bioactive lipids, namely, LPC. In the present in vivo experiments, we showed that endothelial cells in inflamed areas underwent these membrane changes and were likely to be the mediators of CRP dissociation, whereas for our in vitro experiments, we used membrane changes of mononuclear cells to demonstrate the activity of PLA2 inhibitory agents and 1,6-bis PC on CRP dissociation, again demonstrating the ubiquity of this process. In our previous work, we demonstrated that activated platelet membranes could mediate this dissociation process in chronic inflammation. 1 Therefore, this mechanism is independent of the cell type and represents a general mechanism in various pathophysiological settings by which membrane changes caused by cell activation or apoptosis can activate an immune response via binding and dissociation of CRP, thereby resulting in leukocyte activation and infiltration of the area of cellular damage. Our findings potentially link the novel mechanistic role of pCRP to mCRP dissociation with emerging data regarding an association of phospholipase activity and LPC generation with increased cardiovascular risk. 30 In accordance with our previous data, the present findings do not indicate that pCRP possesses intrinsic proinflammatory potential, and CRP was not deposited outside areas of focal inflammation, which confirms the findings of a recent study in which pCRP infusions in healthy volunteers showed no proinflammatory effect. 31 The ability of CRP to mediate any inflammatory effects was dependent on a preexisting localized inflammatory microenvironment with PLA2-mediated membrane changes. In the clinical setting, this is reflected by the fact that levels of circulating pCRP rise 6 to 12 hours after the inflammatory insult. 32 This indicates that CRP dissociation is a modulator, in particular an amplifier, of an established inflammatory response rather than a first-line defense mechanism. Conversely, patients with a chronic mild elevation of circulating CRP levels have been found in numerous studies to be at increased cardiovascular risk. 33 In this setting, local dissociation of circulating pCRP in the inflamed intima of preatherosclerotic lesions might drive atherogenesis.
As a further proof for the relevance of the CRP dissociation process in aggravating the inflammatory response, the recently described compound 1,6-bis-PC was used. This agent acts by stabilizing CRP in a decameric form. 5 This stabilization prevents CRP dissociation in vitro. 25 We were able to show that the inhibition of pCRP dissociation by 1,6-bis-PC abolished the proinflammatory effects of CRP, a powerful inductive proof that demonstrates the relative importance of CRP in promoting innate immunity. The identification of this novel therapeutic approach may support the development of further compounds that are suitable for clinical use. However, it must be taken into consideration that the therapeutic inhibition of mCRP generation might reduce the proangiogenic effect of mCRP that has been described recently. 34 Inflammation as such is not necessarily harmful, but uncontrolled inflammation may be detrimental in conditions such as ischemia/ reperfusion injury. Similarly, the proangiogenic effects of mCRP may be beneficial; however, in the context of an exaggerated inflammatory response, they may have less relevance. Therefore, targeting the effects of mCRP may be a valuable therapeutic strategy in these conditions.
Whereas the cremasteric muscle inflammation model served as a proof-of-concept model to identify the mechanism of CRP aggravated inflammation, we performed a rat left anterior descending coronary artery ligation model to confirm the relevance of this mechanism in a myocardial infarction. Previous animal models of myocardial infarction have found that CRP directly contributes to myocardial cell death and necrosis. 5, 7 This finding is consistent with observational studies after myocardial infarction in humans, which have found that the peak serum (p)CRP level correlates with adverse clinical outcomes. 35 The mechanistic link establishing how CRP contributes to inflammation has been missing and is now elucidated by the present study. Histological studies have found that CRP and complement components (most often component C1q) can be found to be colocalized in myocardial tissue during acute myocardial infarction. 36 We show that the depletion of serum complement abrogates any adverse effect of CRP, which strongly implies complement involvement in CRP pathogenesis. However, both pCRP and C1q are found independently in the plasma with no recognized interaction. 37 In contrast to pCRP, mCRP is a potent ligand of the complement component C1q. 38 The identification of an intermediate conversion step in the injured myocardial tissue is an elegant solution to these conflicting observations. The data obtained in our animal model supplement those previously published by Pepys et al, 5 because we have provided data to suggest that the mechanism of action of 1,6-bis-PC is to prevent mCRP formation by inhibiting pCRP binding and dissociation, which in turn reduces localized inflammation and tissue injury.
We conclude that in inflamed tissue, pCRP is dissociated, and the resulting mCRP is deposited and aggravates as well as localizes inflammatory responses such as leukocyte activation/infiltration. In inflammation, local membrane changes occur, and the present results indicate that these are induced by activation of PLA2 and subsequent exposure of bioactive lipids that mediate the conformational changes of pCRP. Therefore, the blocking of pCRP dissociation to a monomeric form or the inhibition of proinflammatory mCRP activity is a promising therapeutic strategy with the potential to offer a novel treatment approach in a wide range of inflammatory disorders.
CLINICAL PERSPECTIVE
C-reactive protein (CRP) is an independent risk factor for cardiovascular events. Chronic mild elevations in serum CRP are associated with the progression of atherosclerosis. After myocardial infarction, the peak serum CRP correlates with adverse outcomes such as heart failure and death. Despite such strong associative studies, there has been considerable controversy as to whether elevated serum CRP is a causative factor in cardiovascular disease or merely correlates with atherosclerosis and myocardial infarction. Recently, we have shown that on binding to damaged cell membrane, pentameric (p) CRP can undergo dissociation to a proinflammatory, monomeric (m) CRP in a number of inflammatory settings. In this study, using both animal and human data, we show that CRP undergoes dissociation at sites of inflammation, including striated and cardiac muscle, as well as at atherosclerotic plaques. This process is dependent on the action of phospholipase A2, which generates lysophosphatidylcholine on membrane surfaces. This enables pCRP binding and its dissociation to mCRP, which then is deposited and via its proinflammatory effects acts to amplify and localize inflammation, contributing to aggravation of tissue damage. Most important, we show that blocking pCRP dissociation, either by preventing the aforementioned membrane changes by inhibition of phospholipase A2 or by inhibiting CRP dissociation by the compound 1,6-bis(phosphocholine)-hexane, prevents detrimental proinflammatory CRP effects. Therefore, we identified the blocking of pCRP dissociation to mCRP and thereby the prevention of proinflammatory mCRP activity as a promising therapeutic strategy that offers the potential of a novel treatment approach in a wide range of inflammatory disorders, including atherosclerosis and myocardial infarction.
!
Supplemental Material
Methods
Reagents
The anti-pCRP antibody clone 8D8 and anti-mCRP antibody clone 9C9 were generated and characterized for conformation-specificity as described 16 and used as hybridoma supernatant. The aforementioned reagents were kindly provided by Dr.
Larry Potempa (College of Pharmacy, Roosevelt University, Schaumburg, USA). 
Immunohistology of human tissue samples
Tissue samples were obtained from 11 patients receiving reconstruction of soft tissue defects after traumatic injuries of the lower extremity by means of free muscle transfer as described previously 2 . The first sample was taken intra-operatively Human atherosclerotic plaques derived from carotid endarterectomy were stained as described above. After incubation with HRP-labeled anti-mouse antibody (Dako, Glostrup, Denmark) reaction products were stained with HistoGreen substrate kit for peroxidase (Linaris, Dossenheim, Germany) resulting in a green reaction product.
For staining of human myocardial tissue samples were obtained from the CVPath Institute (Gaithersburg, Maryland, USA). All samples had been referred for post-mortem examination and cases where myocardial infarction had been determined to occur between 2 and 5 days prior to death were selected. Myocardial tissue was fixed in formalin prior to examination and histology was performed as described previously 3 .
Samples were prepared as described previously 5 with slight modification.
Slides were de-parafinized in xylene and rehydrated in graded alcohol solutions followed by distilled water. Antigen retrieval was performed by 30 min of heating at 37°C in 2M hydrochloric acid solution. Samples were rinsed and the staining protocol continued as published previously 5 .
Animal model for intravital microscopy studies
! Animal studies were approved by the institutional animal care committee of the University of Freiburg, Germany. Male Wistar rats (Charles River, Sulzfeld, Germany)
weighing 120 -180 g were used. A detailed protocol has been previously described 6 .
Leukocyte-endothelial interactions in the cremaster muscle were observed by intravital microscopy. Leukocytes were labeled by intravenous injection of rhodamine 6G (0.4 mg/kg body weight, Sigma-Aldrich) 7 . Leukocytes were considered adherent to the endothelium if they remained stationary for 20 s or more. Rolling leukocytes were defined as those moving at a velocity less than that of erythrocytes within a given vessel. One to three postcapillary venules with a diameter of 20 -50 !m were chosen for observation; to minimize variability, the same section of cremasteric venule was observed throughout the experiment. Expression Assays). Data were analyzed using the relative standard curve method, with each sample being normalized to GAPDH.
!
In vivo Phosphatidylserine detection
Alexa488 labeled Annexin V solution (Life Technologies) was intravenously injected in male Wistar rats at 1 ml/kg BW. Cremasteric superfusion with LPS (25 ng/ml) was initiated 20 min later. Endothelial associated phosphatidylserine expression in the cremaster muscle was detected via Annexin V specific binding as previously described 10 . The fluorescence signal was measured by digital intravital epifluorescence microscopy in 20 min intervals (n=3).
In vivo pCRP tracking and mCRP detection
For some intravital experiments, pCRP was fluorescently labeled with Alexa594 according to the manufacturer's protocol (Protein Labeling Kit, Life Technologies) to form stable dye-protein conjugates (L-pCRP).
For the detection of mCRP Alexa488 labeled mCRP binding aptamer (mCRPApt.) was intravenously injected (2.5 !g/ml serum concentration) 100 min after LPS superfusion (25 ng/ml) and application of L-pCRP (25 !g/ml) as previously described in the presence or absence of ONO (10 !M). The fluorescence signal was assessed after 120 min (n=3). For in vitro testing a collagen matrix was coated with pCRP and mCRP (25 !g/ml) followed by incubation at 4°C overnight. Blockade with 1% BSA was followed by addition mCRP-Apt. for 1 hour at RT at various concentrations. After extensive washing against PBS-Ca-Mg aptamer binding was quantified using fluorescence spectroscopy.
Pro-inflammatory testing of mCRP-Apt. was conducted in a static monocyte adhesion assay described below in the presence or absence of mCRP-Apt. at 1 and 5 !g/ml.
!
Measurement of ROS generation
After intravital microscopy rats were killed by exsanguination. Mononuclear cells were isolated from whole blood by Ficoll density gradient centrifugation. ROS formation was determined by electron spin resonance spectroscopy (ESR) using CMH (1 mM, 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine, Noxygen, Elzach, Germany) as the spin label and was prepared as described by Kuzkaya et al. 11 . Cell count was determined and 500 !l of cell suspension were incubated at 37°C for 30 min with 25 !g/ml CMH (1 mM). The oxidation of spin probe CMH by ROS generated stable 3-methoxycarbonyl-proxyl radicals (CM . ) 12 expression.
